BioCryst (BCRX) Q4 Earnings: How Key Metrics Compare to Wall Street Estimates

Group 1 - BioCryst Pharmaceuticals reported revenue of $131.53 million for the quarter ended December 2024, representing a 40.8% increase year-over-year [1] - The earnings per share (EPS) for the quarter was -$0.13, an improvement from -$0.28 in the same quarter last year [1] - The reported revenue exceeded the Zacks Consensus Estimate of $130.8 million by 0.56%, while the EPS fell short of the consensus estimate of -$0.06 by 116.67% [1] Group 2 - BioCryst's revenue from ORLADEYO in the U.S. was $106.97 million, slightly above the average estimate of $106.61 million [4] - The revenue from ORLADEYO outside the U.S. was $17.21 million, surpassing the average estimate of $14.10 million [4] - Total revenue from ORLADEYO was $124.19 million, compared to the estimated $121.30 million, marking a 36.6% increase from the previous year [4] Group 3 - Over the past month, BioCryst shares have returned +4.2%, contrasting with a -2.2% change in the Zacks S&P 500 composite [3] - The stock currently holds a Zacks Rank 3 (Hold), indicating expected performance in line with the broader market [3]